2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1106

Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Peripheral Blood Mononuclear Cells of Systemic Sclerosis Patients: Correlation with Disease Specific Manifestations
Abstract Number: 1047

Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway
Abstract Number: 2714

Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis
Abstract Number: 428

Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness
Abstract Number: 2593

Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
Abstract Number: 606

Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Abstract Number: 1257

Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
Abstract Number: 1213

Simplified Salivary Gland Ultrasonography for Sjögren Syndrome and Sicca Symptoms: Experience from a Single Medical Center in Taiwan
Abstract Number: 1533

Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Abstract Number: 1067

Simulating the Pathogenesis of Arthritis in Vitro By Developing a Human-Based Multicomponent 3D Joint Model
Abstract Number: 781

Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
Abstract Number: 2903

Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Abstract Number: 1897

Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway
Abstract Number: 928

Single Cell RNA-Sequencing of Rheumatoid Synovial Fibroblasts Reveals a Disease-Associated Spatial Gradient Modulated By Inductive Notch Signaling
Abstract Number: 77

Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].